Choosing POAF Prophylaxis for a Patient Whose Lungs Are the Reason to Avoid the Best Drug for It
A 69-year-old man with moderate COPD faces real elevated risk for atrial fibrillation after his CABG. The single most effective prophylactic drug for that exact outcome carries a rare but genuine pulmonary toxicity risk in the one organ system he can least afford to gamble with.
Dennis R., a 69-year-old man, spent thirty years working construction before COPD from decades of smoking — he quit twelve years ago, but not before the damage was done — made the physical demands of the job untenable, and he moved to a desk role estimating jobs until his retirement two years ago. His FEV1 runs at 58% predicted on his most recent pulmonary function testing, managed with a long-acting bronchodilator and occasional rescue inhaler use, stable without recent exacerbation. That number is the one the team keeps returning to: it is not severe obstruction, but it is a meaningfully reduced ceiling, and it describes how much room he has left if something takes more of it away.
He presents today for triple-vessel CABG after progressive exertional angina that finally outpaced what his lungs alone could explain. His age and the surgery itself put him at real, elevated risk for new atrial fibrillation in the days after his operation — a common complication the team routinely tries to prevent with prophylactic antiarrhythmic therapy, most often amiodarone given its established efficacy. What complicates the routine choice in his case is that same pulmonary reserve. Amiodarone carries a rare but real risk of acute pulmonary toxicity, and while that risk stays uncommon even with a short perioperative course, the relevant question is not how often it happens but what happens to him if it does. A patient starting from a normal FEV1 who loses lung function to an idiosyncratic drug reaction has somewhere to fall to; a patient already at 58% predicted has considerably less. His baseline QTc of 418ms and normal renal function are the other half of the picture, because between them they describe how much room he has for the obvious alternative.
Choosing the antiarrhythmic for a patient whose lungs complicate the usual answer
I'd give him standard prophylactic amiodarone. It's the most effective drug we have for preventing exactly the complication he's at real risk for, and a short perioperative course carries a much lower cumulative toxicity burden than the chronic dosing that produces the pulmonary and thyroid problems amiodarone is known for.
I'd avoid amiodarone here specifically because of his COPD. The acute pulmonary toxicity risk is rare, I'll grant that, but it isn't zero even with a short course, and he has meaningfully less pulmonary reserve to absorb that complication if it happens than a patient with normal lung function would. I'd use sotalol instead.
I recognize sotalol carries its own real risk — QT prolongation and torsades — and I'm not pretending it's risk-free. But that risk is monitorable with serial ECGs and dose-adjustable in real time, which is a meaningfully different risk profile than an idiosyncratic pulmonary reaction we can't predict or titrate around once it starts.
That's a reasonable way to frame the tradeoff, and I don't think I can argue the pulmonary risk is truly negligible in a patient whose baseline reserve is already reduced — you're right that a low-probability event matters more when the patient has less room to absorb it if it occurs.
I'm comfortable with sotalol given his normal baseline QTc and renal function, both of which keep his torsades risk relatively low. I'd want daily ECGs through his admission to monitor QT interval, which is a reasonable trade for avoiding a complication that would hit him harder than most.
Agreed: sotalol started postoperatively with daily ECG monitoring for QTc, rather than amiodarone. His POAF prophylaxis proceeded without a documented arrhythmia through his admission and without QTc prolongation beyond an acceptable threshold on serial monitoring.
Not agreed as a general rule: at what degree of pulmonary impairment the amiodarone-pulmonary-toxicity risk should routinely tip the decision toward sotalol for future patients, given that his own FEV1 of 58% is a moderate, not severe, degree of COPD. Both voices treated today's decision as reasonable for his specific severity without setting a fixed threshold for milder or more severe COPD patients going forward.